(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least one prior therapy. The approval is based on the … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anti-CD38 antibody, autologous stem cell transplant, bortezomib, CACA, Category I Recommendation, Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology, clinical data, CSCO, dexamethasone, Global Head of Oncology, ICARIA-MM phase 3 study, innovative regulatory pathways, innovative therapies, IsaFiRsT real-world study, Lecheng Pilot Program, lenalidomide, local authorities, medical community, National Medical Products Administration, newly diagnosed multiple myeloma, NMPA, Olivier Nataf, overall response rate, overall survival, Pd, pomalidomide, R/R MM, real-world evidence, regulatory submission, relapsed or refractory multiple myeloma, RWE, Sanofi, Sanofi in China, Sarclisa
(IN BRIEF) GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new version, expected to be available from January 2025, eliminates the need for reconstitution, offering a … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged administration, adults 50 and over, antigen, AS01B adjuvant system, chickenpox, FDA, glycoprotein E, GSK, healthcare community, healthcare professionals, immune response, immunodeficiency, immunosuppression, liquid adjuvant, lyophilised, non-live vaccine, Prefilled Syringe, recombinant subunit vaccine, Recombinant Zoster Vaccine, reconstitution, RZV, safety, Shingles, shingles prevention, shingles vaccine, Shingrix, Shingrix approval, vaccine composition, Vaccine Innovation, vaccine presentation, vaccine safety, varicella, varicella-zoster virus
(IN BRIEF) Empa researchers have developed a groundbreaking 3D-printed, biodegradable fungal battery, capable of powering sensors for agriculture and research in remote regions. This living battery uses two types of fungi, a yeast fungus and a white rot fungus, to … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 3D printed, 3D printing, agriculture, biodegradable, Carolina Reyes, cellulose, cellulose nutrients, electrical engineering, electricity, electrochemical techniques, Empa, fungal battery, fungi, Gebert Rüf Stiftung, Gustav Nyström, longevity, materials science, METABOLISM, microbial fuel cell, Microbials funding program, non-toxic, power, remote regions, RESEARCH, simple sugars, sustainability, sustainable power solutions, temperature sensor, white rot fungus, yeast fungus
(IN BRIEF) Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm’s expertise in customized nucleic acids with Evonik’s advanced lipid and lipid nanoparticle (LNP) drug product development solutions. This collaboration aims … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged active ingredients, capping library screening, clinical trials, drug delivery, drug development, drug product development, enzymatic biotransformation, Evonik, Evonik capabilities, Fill & Finish, gene delivery, gene therapies, GMP manufacturing, Health Care Business, Kris S. Choi, life sciences sector, lipid nanoparticle, lipids, liposomes, LNP, mRNA development, mRNA-LNPs, North America manufacturing, nucleic acid medicines, nucleic acid therapeutics, nucleic acid therapies, Nutrition & Care division, oligonucleotides, partnership, pharmaceutical companies, RNA market, RNA therapeutics, siRNAs, small molecules, SmartCap® technology, South Korea, ST Pharm, strategic partnership, Yann d'Hervé
(IN BRIEF) Researchers at Empa and the Cantonal Hospital of St. Gallen are developing new nanocomplexes to combat antibiotic-resistant bacteria and protect eye tissue following cataract surgery. Supported by the Heinz A. Oertli Fund for Ophthalmology, these nanocomplexes, based on … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antibiotic-Resistant Infections, Empa, Eye Surgery, Mihyun Lee, Nanocomplexes, safety
(IN BRIEF) Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression narrowly missed statistical significance, promising efficacy trends were observed, … Read the full press release
(IN BRIEF) The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS), following positive results from the HERCULES phase 3 study. The study showed tolebrutinib delayed disability progression by 31% and … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Dr. Erik Wallström, FDA, Progressive Multiple Sclerosis, safety, Sanofi, tolebrutinib
(IN BRIEF) Roche has received CE certification for its enhanced cobas® 6800/8800 systems 2.0, introducing significant improvements in laboratory diagnostics. The upgrade streamlines operations by reducing downtime, consolidating test menus, and increasing throughput, supported by innovative TAGS technology that detects … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged cobas Systems 2.0, Matt Sause, Molecular Diagnostics, Roche, safety
(IN BRIEF) Roche’s Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). Serving over nine … Read the full press release
(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boston University, Cardiometabolic Research, Chronic kidney disease, Denmark, Dr. Thomas Hanke, Evotec, Harvard University, Joslin Diabetes Center, LAB eN² Program, Mass General Brigham, metabolic syndrome, Novo Nordisk, Obesity, partnership, type 1 diabetes, Uli Stilz
(IN BRIEF) Roche presented new data at the ASH 2024 meeting highlighting the effectiveness of its bispecific antibodies, Columvi and Lunsumio, in treating lymphomas. Long-term studies show durable remissions and immune system recovery with fixed-duration therapies, while real-world data emphasize … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged ASH 2024, Bispecific Antibodies, Columvi, Levi Garraway, Lunsumio, Lymphoma Treatment, Roche, safety
(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged 96-week results, asciminib, ASH Annual Meeting, chronic myeloid leukemia, CML care, discontinuation rate, imatinib, major molecular response, MMR, National Comprehensive Cancer Network, NCCN, newly diagnosed settings, Novartis, oncology, Ph+ CML-CP, Phase II ASC2ESCALATE trial, Phase III ASC4FIRST trial, Philadelphia chromosome-positive chronic myeloid leukemia, safety, Scemblix, Second-Line Treatment, severe adverse events, standard-of-care, TKIs, tolerability, tyrosine kinase inhibitors
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), potentially becoming the first perioperative immunotherapy in this curative-intent setting. Supported by results from the NIAGARA Phase III trial, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, bladder cancer, FDA, Imfinzi, Perioperative Immunotherapy, safety, Susan Galbraith
(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Ariceum Therapeutics, Critical Medical Radionuclides, Dr. Harald Hasselmann, Eckert & Ziegler, Healthcare, Manfred Rüdiger, partnership, sustainability
(IN BRIEF) Boehringer Ingelheim has launched EURICAN® L4, a new vaccine designed to protect dogs from leptospirosis, a potentially fatal disease spread through contaminated soil and water. Available in France and expanding across Europe in 2025, the vaccine targets four … Read the full press release
(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic testing platform. Opening in 2026, the 8,000-square-meter site will house operations across research, manufacturing, and regulatory functions, focusing on advancing … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Spain, Technology
Tagged Barcelona, Innovation Hub, partnership, QIAGEN, QIAstat-Dx Operations, sustainability, Thierry Bernard
(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Dr. Harald Hasselmann, Eckert & Ziegler, EU, Healthcare, safety, Theralugand®, wellness
(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The solution provides a convenient, twice-daily alternative to tablets, … Read the full press release
(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). The approval, based on the Phase III NATALEE trial, … Read the full press release
(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approximately $1 billion. Poseida stockholders may also receive up to $4.00 per share … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged acquisition, Aviv Regev, cell therapy, INNOVATION, Levi Garraway, partnership, Poseida Therapeutics, Roche, sustainability, USA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?